Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.50

    ▲ 1.44 (13.02%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ 0.04 (8.89%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Oasmia Pharmaceutical: Edison Open House Healthcare 2022

Vivesto — 3 videos in collection

More on this equity

Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.

• Tell us about Oasmia and provide a high-level overview of its ongoing transformation.
• What can be expected from the imminent European launch of Apealea and what are your commercialisation plans?
• Please describe your ‘string of pearls’ strategy and how you are using it to build a diversified oncology portfolio.
• Please provide an update on the development of Cantrixil and the planned next steps, as well as on your other clinical asset, docetaxel micellar?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

Oasmia Pharmaceutical – executive interview

Healthcare

Oasmia Pharmaceutical – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free